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ABSTRACT
Introduction: Good treatment adherence is
important in the effective management of
psoriasis and is related to both the frequency
of applications and the amount of product used
versus the recommended dose. The efficacy and
safety of fixed combination calcipotriol 50 lg/g
(Cal) and betamethasone 0.5 mg/g as
dipropionate (BD) in the treatment of psoriasis
is well established; an aerosol foam formulation
has been developed to enhance adherence. This
subanalysis from the Phase III PSO-FAST study
evaluates the amount of Cal/BD foam used
during treatment and the association between
the extent and severity of baseline disease.
Methods: Patients (C18 years) with
mild-to-severe body psoriasis were randomized
3:1 to once-daily Cal/BD foam or vehicle. The
amount of Cal/BD foam and vehicle used over
the 4-week study period was evaluated according
to three baseline disease assessments: extent of
body surface area (BSA) affected by psoriasis,
physician’s global assessment of disease severity
(PGA) and modified psoriasis area and severity
index (mPASI). Treatment success and mPASI75
rates were assessed according to bodymass index
(BMI) and body weight.
Results: 323 patients were randomized to Cal/
BD foam and 103 to vehicle. At week 4, the
mean total amount of Cal/BD foam used was
120.8 g (n = 293), which was similar to the
amount of vehicle used (128.9 g; n = 98). The
total amount of Cal/BD foam used at week 4 was
greater with increasing BSA and increasing
severity of baseline PGA and mPASI.
Throughout the study, 93.1% of patients in
the Cal/BD foam group and 99.0% of patients in
the vehicle group missed B10% of treatment
applications. Treatment success and mPASI75
rates were generally similar when stratified
according to BMI and body weight.
Conclusions: This subanalysis demonstrates
that Cal/BD aerosol foam is used appropriately
and is effective for the treatment of psoriasis,
independent of BMI and the extent or severity
of disease.
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INTRODUCTION
Therapeutic guidelines for psoriasis recommend
the topical use of corticosteroids and vitamin D3
analogs as first-line treatment, either as separate
products (used together) or as a fixed
combination treatment [1]. Treatment
adherence has been recognized as an important
issue in the management of chronic
inflammatory skin diseases such as psoriasis [2].
Although many patients can manage their
psoriasis with topical therapy alone [1, 3, 4],
adherence remains a significant issue. Adherence
is related to both the frequency of applications
and the amount of product used compared with
the recommended dose; a systematic literature
review found that the frequency of topical
treatment application in randomized controlled
trials ranged from 55% to 100%, while patients
applied between 35% and 72% of the
recommended dose [2]. A number of reasons for
poor adherence to topical therapy were
identified, including a lack of efficacy, excessive
time applying the medication, and poor
cosmetic characteristics [2]. Adherence was
shown to be greater for once-daily treatment as
compared with twice daily [2]. Studies have also
shown that the topical vehicle used can impact
on adherence [5, 6]; patients generally prefer a
vehicle that is simple and fast to apply, quickly
absorbed and not greasy [7].
The efficacy and safety of the fixed
combination of calcipotriol 50 lg/g (Cal) and
betamethasone 0.5 mg/g as dipropionate (BD)
has been confirmed in long-term trials [8–11].
The ointment and gel formulations of this fixed
combination are established first-line
treatments for psoriasis [12]. An aerosol foam
formulation of the fixed Cal/BD combination
has been developed to enhance adherence and
increase the therapeutic options available to
patients. Previous Cal/BD aerosol foam studies
have shown greater in vitro skin penetration
compared with other formulations [13], and a
significantly greater anti-psoriatic effect over
4 weeks of treatment than Cal/BD ointment
[14, 15], gel [16], and individual active
ingredients [17], with a comparable tolerability
profile [15–17]. In a large, double-blind, Phase
III, 4-week study in patients with psoriasis
vulgaris (PSO-FAST [NCT01866163]), treatment
with Cal/BD aerosol foam led to significantly
greater treatment success rates (53.3% vs. 4.8%;
P\0.001) and lower mean modified psoriasis
area and severity index (mPASI; excluding head;
2.0 vs 5.5; P\0.001) scores compared with
aerosol foam vehicle [18].
This subanalysis from the PSO-FAST study
evaluates the amount of Cal/BD aerosol foam
used during treatment and the association
between the extent and severity of baseline
disease, in patients with psoriasis.
METHODS
Patients and Study Design
Patients eligible for inclusion in the PSO-FAST
study were C18 years of age with a clinical
diagnosis of mild-to-severe body psoriasis.
Patients had between 2% and 30% of their
body surface area (BSA; i.e., trunk and limbs)
affected by the disease, with an mPASI score of
C2. Full inclusion and exclusion criteria have
been reported in Leonardi et al. [18].
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PSO-FAST (Cal/BD aerosol foam in PSOriasis
vulgaris, a Four-week, vehicle-controlled,
efficacy And Safety Trial) was a Phase III,
multicenter, double-blind study. Patients were
randomized (3:1) to Cal/BD aerosol foam or
aerosol foam vehicle once daily for up to
4 weeks.
Assessments
The total amount of Cal/BD foam used by each
patient during the 4-week study was determined
by calculating the difference between the
weight of the cans dispensed and the weight
of the returned cans, multiplied by a correction
factor of 0.41 to account for the propellant
gases. Adherence was assessed by calculating the
percentage of missed treatment applications
(B10%,[10–B20%,[20–B30%,[30–B40%,
[40–B50% and[50%), as follows: the number
of applications of Cal/BD foam missed for a
particular visit interval was divided by the total
number of days for the interval, multiplied by
100.
Treatment success was defined as the
proportion of patients who were clear or
almost clear of disease with at least a two-step
improvement at week 4, according to the
physician’s global assessment of disease
severity (PGA). The rate of treatment success
was the primary endpoint of the study and the
data have been reported in Leonardi et al. [18].
Analysis
The total amount of Cal/BD foam used during
the study was evaluated according to three
baseline disease assessments: the extent to
which a patient’s BSA was affected by psoriasis
vulgaris; PGA; and mPASI. The proportion of
patients achieving treatment success was
stratified according to body weight and body
mass index (BMI).
Compliance with Ethics Guidelines
The institutional review boards of all
investigational sites approved the protocol.
This study was conducted according to Good
Clinical Practice guidelines and the principles of
the Declaration of Helsinki 1964, as revised in
2013. All patients provided written informed
consent prior to enrollment. The
ClinicalTrials.gov identifier is NCT01866163.
RESULTS
In total, 323 patients were randomized to Cal/
BD foam and 103 to vehicle; 313 (96.9%) and 99
(96.1%) patients, respectively, completed the
study. Of the 14 patients who withdrew, eight
were lost to follow-up.
The overall mean (±standard deviation) total
amount of Cal/BD aerosol foam used after
4 weeks was 120.8 ± 85.7 g (n = 293/323),
which was similar to the mean total amount
of aerosol foam vehicle used (128.9 ± 92.9 g;
n = 98/103). The mean amount of drug used per
week was also similar between treatment
groups: Cal/BD aerosol foam 29.8 g/week,
vehicle 32.1 g/week. The mean amount of Cal/
BD aerosol foam used was consistent from
baseline to week 1 (29.9 g/week), from week 1
to week 2 (28.5 g/week), and from week 2 to
week 4 (30.2 g/week).
The total amount of Cal/BD aerosol foam
used at week 4 was greater with increasing BSA
and increasing severity of baseline PGA and
mPASI (Fig. 1a–c). Most patients enrolled in the
PSO-FAST study had B10% of their BSA
involved at baseline (n = 227), and used on
average between 88.3 and 117.6 g of Cal/BD
Dermatol Ther (Heidelb) (2016) 6:667–673 669
aerosol foam during treatment (Fig. 1a).
Throughout the 4-week treatment period,
93.1% of patients in the Cal/BD aerosol foam
group and 99.0% of patients in the vehicle
group missed B10% of treatment applications.
Treatment success rates were generally
similar irrespective of body weight and BMI
(Fig. 2a, b). Similarly, additional evaluation of
mPASI75 rates (i.e., the proportion of patients
who achieved a 75% decrease in mPASI) did not
demonstrate a difference in response according
body weight or BMI (data not shown).
DISCUSSION
In the Phase III PSO-FAST study, most patients
had mild-to-moderate disease severity
(BSA\10%) and, on average, used 88–118 g of
Cal/BD foam. The amount of Cal/BD aerosol
foam used was comparable to vehicle and the
product was used consistently throughout the
4-week study, suggesting that treatment
persistence with the foam was good. In
addition, patients used an appropriate amount
of Cal/BD aerosol foam for the extent and
Fig. 1 Mean total amount of Cal/BD aerosol foam used
at week 4 by baseline a BSA; b PGA; and c mPASI. BD
betamethasone 0.5 mg/g as dipropionate, BSA body
surface area, Cal calcipotriol 50 lg/g, mPASI modiﬁed
psoriasis area and severity index, PGA physician’s global
assessment of disease severity, SD standard deviation
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severity of their psoriasis at baseline, since the
mean total amount of Cal/BD aerosol foam used
increased with increasing baseline BSA, PGA
and mPASI.
The primary analysis demonstrated that
significantly more patients using Cal/BD foam
achieved treatment success versus vehicle and
mean mPASI score was significantly lower for
patients using Cal/BD foam than vehicle at
week 4 [18]. This subanalysis shows that the
effectiveness of Cal/BD aerosol foam, based on
treatment success rates, was not affected by
body weight or BMI, so can be used in all
patients irrespective of their size or extent of
their BSA that is covered with plaques (as long
as it is within the approved label). It has
previously been suggested that BMI may be a
prognostic factor for the response to treatment
in psoriasis [19]; indeed, a number of studies
have shown that some biologic therapies are
less effective in patients with a BMI C25–30
compared with a BMI\25 [19–23].
One limitation of this analysis is that the
regular monitoring that occurred during this
clinical study of relatively short duration may
reinforce patient adherence compared with that
observed in the real world. Outside of the clinical
trial setting, some patients are unintentionally
non-adherent with treatment (e.g., because they
forget to use the medication as directed), whilst
others are intentionally non-adherent (e.g.,
altering or stopping treatment because of
perceived ineffectiveness or side effects) [24].
CONCLUSION
In conclusion, this subanalysis from the
PSO-FAST study demonstrates that Cal/BD
aerosol foam is used appropriately and is
effective for the treatment of psoriasis,
independent of BMI and the extent or severity
of disease.
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